COVID VACCINE CHEAT SHEET

DATE: Sept 9, 2021 – Most recent changes highlighted in yellow

	Pfizer-BioNTech COVID-19 Vaccine	Moderna mRNA-1273
Туре	mRNA vaccine	mRNA vaccine
Handling	From the freezer to room temperature - 30 minutes to thaw	From the freezer to room temperature - 1 hour to thaw
	From the freezer to the refrigerator – full tray requires 3 hours to	From the freezer to the refrigerator – 2.5 hours to thaw
	thaw	Requires 15 minutes at room temperature before administration.
	Requires 15 minutes at room temperature before reconstitution.	After first puncture, it can be stored at room temperature or
	After first puncture must be used within 6 hours	refrigerated but must be discarded after 24 hours
Storage	Frozen between -80°C to -60°C for up to 6 months.	Frozen at -20°C (-25°C to -15°C) for up to 6 months.
	Protect from light. Diluent can be stored at room temperature.	Protect from light.
Thawing of vaccine	May be thawed and stored at between +2°C to +8°C for up to 31	May be thawed and stored at +2°C -+8°C for up to 30 days. Do not
	days. Do not refreeze.	refreeze.
	May be stored at room temperature (up to +25°C) for a total accumulation of no more than 2 hours before reconstituting with	May be stored at room temperature for a total accumulation of no more than 24 hours.
	diluent.	more than 24 nours.
Authorized ages for use	≥ 12 years (Health Canada)	≥ 12 years (Health Canada)
	*May be given to clients ≥ 11 years if they are born in 2009 (Ministry of Health)	
	**Preferred for use (over Moderna) for clients age 12-24 years (Ministry of Health)	
Preservatives	None	None
Route	Intramuscular	Intramuscular
Dosage	0.3 mL	0.5 mL
Schedule	Recommended schedule - 2 doses 21 days apart (minimum 19 days)	Recommended schedule - 2 doses 28 days apart (minimum of 21 days)
	Recommended as a 2 nd dose following AstraZeneca / COVISHIELD vaccine at 8 weeks apart (minimum 28 days)	Recommended as a 2 nd dose following AstraZeneca / COVISHIELD vaccine at 8 weeks apart (minimum 28 days)
Reconstitution/Mixing	Reconstitute with 1.8 mL of sodium chloride diluent (supplied by manufacturer)	No reconstitution required
		DO NOT SHAKE – swirl the vial gently between doses
	DO NOT SHAKE – invert gently 10 times	
Appearance	Translucent to white colour after reconstituted	White to off-white suspension that may contain white or
		translucent product-related particulates.

Availability	6 dose multi-dose vials	10 dose or 14 dose multi-dose vial
Latex	None	None
Non-medicinal ingredients	Polyethylene Glycol (ALC-0159 = 2-[(polyethylene glycol)-2000]- N,N-ditetradecylacetamide) ALC-0135 (4-hydroxy-butyl)azanediyl)bis(hexane-6,1- diyl)bis(2hexyldecanoate) 1,2-distearoyl-sn-glycero-3-phosphocholine Cholesterol Dibasic sodium phosphate dihydrate Monobasic potassium phosphate Potassium chloride Sodium chloride Sucrose and Water for injection	Lipids (Polyethylene Glycol ([PEG] 2000 dimyristoyl glycerol [DMG] Lipid SM-102 cholesterol 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]) tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, Sucrose and Water for injection
Contra-indications	Severe allergy to any component in the vaccine (Polyethylene glycol and/or polysorbate) Anyone with current confirmed COVID infection or COVID symptoms Individuals under the age of 12 Hx of myocarditis or pericarditis after a previous dose of COVID vaccine	Severe allergy to any component in the vaccine (Polyethylene glycol, tromethamine, and/or polysorbate) Anyone with current confirmed COVID infection or COVID symptom Individuals under the age of 12 Hx of myocarditis or pericarditis after a previous dose of COVID vaccine
Special Populations	Please refer to most recent guidelines in Ministry of Health COVID-19 Vaccination Recommendations for Special Populations.	Please refer to most recent guidelines in Ministry of Health COVID-19 Vaccination Recommendations for Special Populations.
Other areas for consideration:		
	Interchangeability of mRNA vaccines – NACI's guidance advises that the Pfizer and Moderna COVID-19 vaccines can be safely interchanged for first and second doses if the original mRNA vaccine is not readily available. Clients who received a first dose of an mRNA vaccine should be offered the same mRNA vaccine for their second dose. If the same mRNA vaccine is not readily available, another mRNA vaccine can be offered instead to complete the vaccine series.	

Pfizer-BioNTech product monograph; Moderna COVID-19 Product Monograph; Ministry of Health Administration of Moderna COVID-19 Vaccine Version 3.0 (Jun 18, 2021); Ministry of Health Administration of Pfizer-BioNTech COVID-19 Vaccine Version 6.0 (Jun 18, 2021)